Abbott Laboratories Change in Accounts Receivable 2010-2025 | ABT
Abbott Laboratories annual/quarterly change in accounts receivable history and growth rate from 2010 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- Abbott Laboratories change in accounts receivable for the quarter ending March 31, 2025 was $-0.262B, a 73.51% increase year-over-year.
- Abbott Laboratories change in accounts receivable for the twelve months ending March 31, 2025 was $-1.962B, a 119.46% increase year-over-year.
- Abbott Laboratories annual change in accounts receivable for 2024 was $-0.691B, a 94.1% increase from 2023.
- Abbott Laboratories annual change in accounts receivable for 2023 was $-0.356B, a 423.53% increase from 2022.
- Abbott Laboratories annual change in accounts receivable for 2022 was $-0.068B, a 82.25% decline from 2021.
| Abbott Laboratories Annual Change in Accounts Receivable (Millions of US $) |
|
|---|---|
| 2024 | $-691 |
| 2023 | $-356 |
| 2022 | $-68 |
| 2021 | $-383 |
| 2020 | $-924 |
| 2019 | $-275 |
| 2018 | $-190 |
| 2017 | $-207 |
| 2016 | $-177 |
| 2015 | $-171 |
| 2014 | $-195 |
| 2013 | $-113 |
| 2012 | $36 |
| 2011 | $-670 |
| 2010 | $-395 |
| 2009 | $-388 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $232.407B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $155.727B | 38.99 |
| Stryker (SYK) | United States | $146.049B | 30.54 |
| EssilorLuxottica (ESLOY) | France | $127.608B | 0.00 |
| Medtronic (MDT) | Ireland | $106.425B | 15.09 |
| Haleon (HLN) | United Kingdom | $51.128B | 29.10 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.009B | 0.00 |
| ResMed (RMD) | United States | $35.893B | 26.96 |
| GE HealthCare Technologies (GEHC) | United States | $32.299B | 15.33 |
| Agilent Technologies (A) | United States | $31.909B | 20.73 |
| Terumo (TRUMY) | Japan | $27.168B | 35.29 |
| Insulet (PODD) | United States | $22.874B | 89.79 |
| Koninklijke Philips (PHG) | Netherlands | $21.656B | 15.57 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.236B | 11.71 |
| Baxter (BAX) | United States | $15.652B | 11.69 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.683B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.637B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.175B | 21.49 |
| Lantheus Holdings (LNTH) | United States | $5.228B | 13.19 |
| Prestige Consumer Healthcare (PBH) | United States | $4.233B | 18.91 |
| Perrigo (PRGO) | Ireland | $3.680B | 9.33 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.319B | 24.48 |
| Haemonetics (HAE) | United States | $3.253B | 14.82 |
| Envista Holdings (NVST) | United States | $3.097B | 25.73 |
| GN Store Nord (GNNDY) | Denmark | $2.224B | 18.42 |
| QuidelOrtho (QDEL) | United States | $2.074B | 14.27 |
| LeMaitre Vascular (LMAT) | United States | $1.857B | 41.52 |
| AtriCure (ATRC) | United States | $1.711B | 0.00 |
| Acuren (TIC) | United States | $1.276B | 0.00 |
| Neogen (NEOG) | United States | $1.272B | 16.28 |
| AdaptHealth (AHCO) | United States | $1.212B | 12.30 |
| Kestra Medical Technologies (KMTS) | United States | $1.156B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.109B | 24.95 |
| BioLife Solutions (BLFS) | United States | $1.039B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.990B | 12.65 |
| InMode (INMD) | Israel | $0.927B | 9.34 |
| CeriBell (CBLL) | United States | $0.608B | 0.00 |
| Evolus (EOLS) | United States | $0.593B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.573B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.550B | 0.00 |
| Valneva SE (VALN) | France | $0.535B | 0.00 |
| Owens & Minor (OMI) | United States | $0.510B | 4.23 |
| Capricor Therapeutics (CAPR) | United States | $0.452B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.428B | 0.00 |
| Surmodics (SRDX) | United States | $0.415B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.366B | 0.00 |
| SNDL (SNDL) | Canada | $0.334B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.316B | 11.62 |
| Aurora Cannabis (ACB) | Canada | $0.298B | 53.00 |
| Cresco Labs (CRLBF) | United States | $0.295B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.263B | 22.17 |
| Sanara MedTech (SMTI) | United States | $0.258B | 0.00 |
| ZimVie (ZIMV) | United States | $0.255B | 11.57 |
| Cerus (CERS) | United States | $0.243B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.243B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.229B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.224B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.215B | 0.00 |
| Quanterix (QTRX) | United States | $0.202B | 0.00 |
| Brainsway (BWAY) | Israel | $0.192B | 51.00 |
| Biote (BTMD) | United States | $0.189B | 5.32 |
| TriSalus Life Sciences (TLSI) | United States | $0.189B | 0.00 |
| High Tide (HITI) | Canada | $0.182B | 0.00 |
| Omeros (OMER) | United States | $0.181B | 0.00 |
| Organigram Global (OGI) | Canada | $0.181B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.179B | 14.57 |
| Exagen (XGN) | United States | $0.148B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.137B | 16.92 |
| Jin Medical (ZJYL) | China | $0.118B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.107B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.096B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.60 |
| Agape ATP (ATPC) | $0.087B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.086B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.078B | 0.00 |
| Veru (VERU) | United States | $0.074B | 0.00 |
| InterCure (INCR) | Israel | $0.071B | 0.00 |
| Zynex (ZYXI) | United States | $0.071B | 0.00 |
| Apyx Medical (APYX) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| ImmuCell (ICCC) | United States | $0.058B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.053B | 0.00 |
| United Health Products (UEEC) | United States | $0.052B | 0.00 |
| Modular Medical (MODD) | United States | $0.047B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.17 |
| Rockwell Medical (RMTI) | United States | $0.034B | 0.00 |
| Nephros (NEPH) | United States | $0.029B | 38.86 |
| Safety Shot (SHOT) | United States | $0.021B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.010B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |